A Phase 1 interventional study of empagliflozin/linagliptin FDC in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-16.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
Drug: empagliflozin/linagliptin FDC
Drug pages: Empagliflozin · Linagliptin
empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
Cmax for Linagliptin
Maximum measured concentration of the analyte in plasma (Cmax) for linagliptin
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
Cmax for Empagliflozin
Maximum measured concentration of the analyte in plasma (Cmax) for empagliflozin
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
AUC 0-tz for Linagliptin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for linagliptin
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
AUC 0-tz for Empagliflozin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for empagliflozin
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
AUC0-infinity for Linagliptin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for linagliptin
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
AUC0-infinity for Empagliflozin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for empagliflozin.
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
AUC0-72 for Linagliptin
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours (AUC0-72) for linagliptin
Time frame: 2 hours (h) before the administration in first subject and 0:20 h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, 72:00h after drug administration.
| Milestone | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed) |
|---|---|---|
| Started | 11 | 11 |
| Completed | 11 | 11 |
| Not completed | 0 | 0 |
| Milestone | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed) |
|---|---|---|
| Started | 11 | 11 |
| Completed | 11 | 11 |
| Not completed | 0 | 0 |
Maximum measured concentration of the analyte in plasma (Cmax) for linagliptin
| nmol/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| Cmax for Linagliptin | 15.1 ± 50.6 | 8.43 ± 30.3 |
Maximum measured concentration of the analyte in plasma (Cmax) for empagliflozin
| nmol/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| Cmax for Empagliflozin | 1010 ± 27.1 | 756 ± 27.3 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for linagliptin
| nmol∙h/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| AUC 0-tz for Linagliptin | 348 ± 15.4 | 286 ± 20.5 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable drug plasma concentration (AUC 0-tz) for empagliflozin
| nmol∙h/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| AUC 0-tz for Empagliflozin | 7210 ± 19.1 | 6200 ± 20.6 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for linagliptin
| nmol∙h/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| AUC0-infinity for Linagliptin | 597 ± 20.6 | 526 ± 33.4 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity) for empagliflozin.
| nmol∙h/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| AUC0-infinity for Empagliflozin | 7270 ± 19.1 | 6280 ± 20.4 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours (AUC0-72) for linagliptin
| nmol∙h/L | Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) |
|---|---|---|
| AUC0-72 for Linagliptin | 348 ± 15.4 | 286 ± 20.5 |
Collected over From first drug administration until 7 days thereafter for each treatment arm, up to 8 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empagliflozin 25 mg/ Linagliptin 5 mg (Reference;Fasted) | — | 0/22 (0%) | 0/22 (0%) |
| Empagliflozin 25 mg/ Linagliptin 5 mg (Test;Fed) | — | 0/22 (0%) | 0/22 (0%) |
Treated Set (TS): This analysis set included all 22 randomised subjects who were documented to have taken at least 1 dose of trial medication
| Age, Continuous(Years) | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed) | Total |
|---|---|---|---|
| Mean | 29.00 ± 8.83 | 33.73 ± 9.55 | 31.36 ± 9.30 |
| Sex: Female, Male(Participants) | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 1: Fed-Fasted) | Empagliflozin 25 mg/ Linagliptin 5 mg (Sequence 2: Fasted-Fed) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 11 | 11 | 22 |
Ran from Jul 2016 to primary completion in Oct 2016, 2 months.
Results were first posted in Aug 2018, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Linagliptin